Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Published byChrister Våge Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 2 Estimate of the neoantigen repertoire in human cancer."— Presentation transcript:

1 Fig. 2 Estimate of the neoantigen repertoire in human cancer.
Estimate of the neoantigen repertoire in human cancer. Data depict the number of somatic mutations in individual tumors. Categories on the right indicate current estimates of the likelihood of neoantigen formation in different tumor types. Adapted from (50). It is possible that the immune system in melanoma patients picks up on only a fraction of the available neoantigen repertoire, in which case the current analysis will be an underestimate. A value of 10 somatic mutations per Mb of coding DNA corresponds to ~150 nonsynonymous mutations within expressed genes. Ton N. Schumacher, and Robert D. Schreiber Science 2015;348:69-74 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 2 Estimate of the neoantigen repertoire in human cancer."

Similar presentations

Computational methods for genomics-guided immunotherapy

Computational methods for genomics-guided immunotherapy
Do Now: 1) How do somatic and sex cell mutations differ. 2) A mutation causes the adenine in the following sequence to be changed to a guanine. How does.

Do Now: 1) How do somatic and sex cell mutations differ. 2) A mutation causes the adenine in the following sequence to be changed to a guanine. How does.
Cancer immunotherapy: an update

Cancer immunotherapy: an update
Genetics Lesson 4 Mutations.

Genetics Lesson 4 Mutations.
Socializing Individualized T-Cell Cancer Immunotherapy

Socializing Individualized T-Cell Cancer Immunotherapy
Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.
CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.
Dose-escalation patient response.

Dose-escalation patient response.
Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,
Immunology and the Lynch Syndrome

Immunology and the Lynch Syndrome
A B C Supplementary figure S7

A B C Supplementary figure S7
Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.

Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.
Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.

Distribution of mutations in different groups of genes, in cancer with extreme ML values. Distribution of mutations in different groups of genes, in cancer.
Unit 6 Notes: Cancer & Mutations

Unit 6 Notes: Cancer & Mutations
Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.
Let to development of a class of antibodies (organic molecules) that are known as immune checkpoint inhibitors which are now used for cancer therapies.

Let to development of a class of antibodies (organic molecules) that are known as immune checkpoint inhibitors which are now used for cancer therapies.
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?

The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Similar presentations

Ads by Google